[SARS-CoV-2 vaccines]
- PMID: 33734065
[SARS-CoV-2 vaccines]
Abstract
Control of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require one or more vaccines. Currently, numerous SARS-CoV-2 vaccines are in either pre-clinical or clinical development. Twenty are in fase III development. In this review we summarise available safety and efficacy data of two RNA based vaccines, two non-replication competent vector-based vaccine, one inactivated whole-virus vaccine, and one subunit. All being either approved or nearing approval.
Similar articles
-
Frontrunners in the race to develop a SARS-CoV-2 vaccine.Can J Microbiol. 2021 Mar;67(3):189-212. doi: 10.1139/cjm-2020-0465. Epub 2020 Dec 2. Can J Microbiol. 2021. PMID: 33264067 Review.
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24. Vaccine. 2021. PMID: 33279318 Free PMC article. Review.
-
SARS-CoV-2 vaccine candidates in rapid development.Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121319 Free PMC article. Review.
-
Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.J Infect Dis. 2021 Feb 3;223(2):189-191. doi: 10.1093/infdis/jiaa637. J Infect Dis. 2021. PMID: 33535239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous